A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)

Takashina, Taichi; Asahina, Hajime; Oizumi, Satoshi et al.

International journal of clinical oncology, 2018, 23(6), 1060-1069

Permalink : https://hdl.handle.net/2115/74964

このアイテムのアクセス数:1,246件（2026-10-07 07:16 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
IJCO23_1060 pdf 647 KB 1,319

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/74964
タイトル
A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)
著者
Takashina, Taichi ; Asahina, Hajime ; Oizumi, Satoshi ; Yamada, Noriyuki ; Harada, Masao ; Takamura, Kei ; Yokouchi, Hiroshi ; Harada, Toshiyuki ; Honjo, Osamu ; Ogi, Takahiro ; Morikawa, Naoto ; Kinoshita, Ichiro ; Honda, Ryoichi ; Nakano, Kosuke ; Kanazawa, Kenya ; Amano, Toraji ; Dosaka-Akita, Hirotoshi ; Isobe, Hiroshi ; Nishimura, Masaharu
著者名
Takashina, Taichi
著者名
Asahina, Hajime
e-Rad_Researcher
10421968
著者名
Oizumi, Satoshi
著者名
Yamada, Noriyuki
著者名
Harada, Masao
著者名
Takamura, Kei
著者名
Yokouchi, Hiroshi
著者名
Harada, Toshiyuki
著者名
Honjo, Osamu
著者名
Ogi, Takahiro
著者名
Morikawa, Naoto
e-Rad_Researcher
40343008
著者名
Kinoshita, Ichiro
著者名
Honda, Ryoichi
著者名
Nakano, Kosuke
著者名
Kanazawa, Kenya
著者名
Amano, Toraji
e-Rad_Researcher
70222528
著者名
Dosaka-Akita, Hirotoshi
e-Rad_Researcher
90241322
著者名
Isobe, Hiroshi
e-Rad_Researcher
00208224
著者名
Nishimura, Masaharu
言語
英語
キーワード
Maintenance therapy
Pemetrexed
Bevacizumab
Erlotinib
Non-small cell lung cancer
発行日
2018-12
出版者
Springer
収録物名
International journal of clinical oncology
巻(号)
23(6)
ページ
1060-1069
抄録
Background: This study evaluated the efficacy and safety of switch maintenance erlotinib and bevacizumab after induction therapy with carboplatin/pemetrexed/bevacizumab for non-squamous non-small cell lung cancer (NSCLC) with wild-type EGFR. Methods: Enrolled patients had treatment-naive, advanced non-squamous NSCLC with wild-type EGFR. Carboplatin [area under the curve (AUC) 5.0], pemetrexed (500 mg/m2) and bevacizumab (15 mg/kg) were administered on day 1 every 3 weeks for 4-6 cycles. Maintenance therapy with erlotinib (150 mg/body) on day 1 through 21 plus bevacizumab on day 1 every 3 weeks was continued until disease progression or unacceptable toxicity. The primary endpoint was 6-month progression-free survival (PFS); secondary endpoints included overall survival (OS), overall response rate (ORR), toxicity, and quality of life (QOL). Results: Fifty-one patients were enrolled between September 2011 and June 2014. The median number of cycles for induction and maintenance therapy was 4 (range 1-6) and 4 (range 1-20). Twenty-nine patients (58%) received maintenance therapy. The 6-month PFS rate was 59.5% [95% confidence interval (CI) 45.0-72.6%]. The ORR was 48.0% (95% CI 34.8-61.5%), and disease control rate was 86.0% (95% CI 73.8-93.0%). The median PFS and OS were 6.5 months (95% CI 5.8-7.2 months) and 21.4 months (95% CI 15.9-26.9 months), respectively. Although grades ≥ 3 adverse events were observed in 33 patients (66.0%), most were hematologic; there was no febrile neutropenia. QOL was maintained throughout treatment. Conclusions: Carboplatin/pemetrexed/bevacizumab followed by erlotinib and bevacizumab maintenance showed modest efficacy and was well tolerated in non-squamous NSCLC patients with wild-type EGFR.
資源タイプ
学術雑誌論文
出版タイプ
Accepted Manuscript
権利情報
This is a post-peer-review, pre-copyedit version of an article published in International Journal of Clinical Oncology. The final authenticated version is available online at: http://dx.doi.org/10.1007/s10147-018-1318-z
PISSN
1341-9625
関連情報
PMID
30027464
関連情報 (isVersionOf)
出版社版DOI
https://doi.org/10.1007/s10147-018-1318-z